2019
Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A population-based analysis
Tan W, Trinh Q, Hayn M, Marchese M, Lipsitz S, Nabi J, Kilbridge K, Vale J, Khoubehi B, Kibel A, Sun M, Chang S, Sammon J. Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A population-based analysis. Urologic Oncology Seminars And Original Investigations 2019, 38: 74.e13-74.e20. PMID: 31864937, DOI: 10.1016/j.urolonc.2019.11.008.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCT1a renal cell carcinomaImmediate nephrectomyKaplan-Meier curvesOverall survivalCell carcinomaSurgical resectionRenal massesPatient ageTreatment armsCharlson Comorbidity Index 0Compare OS of patientsLong-term overall survivalInfluence of patient ageCox proportional hazards regression analysisEarly surgical resectionLong-term OSMedian patient ageProportional hazards regression analysisMedian follow-upNational Cancer DatabaseOS of patientsSmall renal massesInverse probabilityRecommended treatment option
2018
Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial
Tan W, Panchal A, Buckley L, Devall A, Loubière L, Pope A, Feneley M, Cresswell J, Issa R, Mostafid H, Madaan S, Bhatt R, McGrath J, Sangar V, Griffiths T, Page T, Hodgson D, Datta S, Billingham L, Kelly J. Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. European Urology 2018, 75: 63-71. PMID: 30274699, DOI: 10.1016/j.eururo.2018.09.005.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerDisease-free survival timeCarcinoma in situBacillus Calmette-GuerinSecond-line therapyTreatment armsComplete responseOpen-labelNo significant differenceBladder cancerCourse of bacillus Calmette-GuerinNon-muscle-invasive bladder cancer patientsBacillus Calmette-Guerin failuresCarcinoma in situ patientsStandard second-line therapyBacillus Calmette-Guerin therapyRecurrence of non-muscle-invasive bladder cancerStandard of care treatmentControlled trialsPapillary bladder lesionsPhase III randomised controlled trialMedian follow-upBladder cancer outcomesSignificant differenceOutcome measures
2013
Efficacy and safety of long‐acting intramuscular testosterone undecanoate in aging men: a randomised controlled study
Tan W, Low W, Ng C, Tan W, Tong S, Ho C, Khoo E, Lee G, Lee B, Lee V, Tan H. Efficacy and safety of long‐acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU International 2013, 111: 1130-1140. PMID: 23651425, DOI: 10.1111/bju.12037.Peer-Reviewed Original ResearchConceptsProstate-specific antigenTestosterone undecanoateTestosterone deficiencyTreatment armsAdverse eventsSex hormone-binding globulinIntramuscular testosterone undecanoateCommon adverse eventsIncreased serum testosteroneHormone-binding globulinLiver function testsCessation of treatmentFasting blood glucosePhysical examination resultsRandomised controlled studySite of injectionTU injectionsPlacebo armSerum TTSerum testosteroneSpecific antigenAdverse reactionsLipid profileFunction testsControlled studies